Breezebio Inc., formerly known as Genedit Inc., has closed $60 million in series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s Nanogalaxy delivery platform.
Kivu Bioscience Inc. has announced receipt of Human Research Ethics Committee approval and clinical trial notification clearance in Australia to initiate a first-in-human trial of KIVU-305, its CEACAM5-targeted antibody-drug conjugate.
Waverley Pharma Inc. has discovered substituted (3-hydroquinazolin-4-one) derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors and thus potentially useful for the treatment of cancer.
Shanghai Meiyue Biotech Development Co. Ltd. has patented heterocyclic derivatives acting as KIT (c-KIT) inhibitors. They are reported to be useful for the treatment of autoimmune, metabolic disease, cancer, diabetes, fibrosis, urticaria, inflammatory and respiratory disorders, among others.
A recent study assessed the applicability of McERV-pseudotyped lentiviral vector particles (McERV-PTLVs) to target cancer cells of glial or neuronal origin.
Augustine Therapeutics NV has divulged thiomethyl carbonyl compounds acting as histone deacetylase 6 (HDAC6) and/or HDAC1 and/or HDAC3 inhibitors. They are reported to be useful for the treatment of inflammatory disorders, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.
Asieris Pharmaceuticals Co. Ltd. and Shanghai Yahong Meditech Co. Ltd. have discovered new poly(ADP-ribose) glycohydrolase (PARG) inhibitors potentially useful for the treatment of cancer.
Researchers from Jiangsu Ocean University reported the synthesis and preclinical evaluation of novel derivatives of SKF-83566, a selective D1 receptor antagonist widely used in dopamine signaling research.
RSS
